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Introduction
Uterine leiomyosarcomas (uLMS), arising from the myometrium, are rare malignancies with an annual incidence rate of 0.4-0.9/100,000 women. 1 Although prognosis depends on the stage, uLMS are generally aggressive tumors, with 5-year survival rates ranging from 16% for stage IV uLMS to 57% for stage I uLMS. 2 The cornerstone of treatment is hysterectomy with or without bilateral salpingo-oophorectomy. 3 However, even after radical surgery, at least 50% of patients experience intraperitoneal and/or distant relapses. 4 Adjuvant treatment options for LMS patients include cytotoxic drugs, such as doxorubicin 6 ifosfamide, gemcitabine 6 docetaxel and trabectedin, that usually have only limited effect. 3 Recently, the multi-kinase inhibitor pazopanib showed modest survival effects in the randomized, placebo-controlled PALETTE trial. Although no significant improvement was noted in overall survival (OS), pazopanib prolonged progression-free survival (PFS), which led to its approval as a second-line treatment in LMS. 5 A more promising compound is olaratumab, a platelet-derived growth factor receptor-alpha inhibitor, which recently received accelerated approval as first-line treatment for LMS. The approval was based on a randomized phase II trial that showed superior OS (26.5 months) in the group treated with olaratumab plus doxorubicin compared to doxorubicin alone (14.7 months). 6 Because of the rarity and limited availability of uLMS samples, most published studies focusing on uLMS so far consist of small sample sets (<20 patients) that do not allow for large-scale genomic analyses. The identification of driver events is further complicated by the polyploid and copy number-instable nature of uLMS, which gives rise to complex karyotypes. 7 Chromosomal aberrations have been reported across the entire uLMS genome, with frequent deletions affecting chromosomal arms 2p, 2q, 10q and 13q, as well as amplifications on 1p, 5q and 8q. 7 However, these regions are very broad and contain many potential cancer driver genes. Recently, a few studies managed to perform transcriptome analyses in up to 50 uLMS patients, identifying expressionbased molecular subtypes of LMS that correlated with survival. [8] [9] [10] Some genetic 9, 11 and transcriptome-based 9,10 studies also included extrauterine LMS (euLMS), which arise from smooth muscle cells located throughout the body with exclusion of the uterus. [9] [10] [11] Indeed, uLMS and euLMS show many similarities and are often difficult to distinguish on a molecular level. [9] [10] [11] Another recent study performed exome sequencing of 19 uLMS, revealing, in addition to frequent mutations in TP53 and MED12, also a number of mutations in the chromatin remodeler ATRX. 12 While these efforts represent a promising and valuable attempt to decipher the molecular genetic basis of uLMS, aberrations affecting genes or pathways that could be exploited as potential therapeutic targets have not yet been reported.
Here, we used a high-throughput sequencing approach to integrate various types of genetic data, including somatic amplifications and deletions, mutations and gene fusions, as well as gene expression data, with the aim of identifying novel genes and pathways recurrently affected in uLMS. Through a multi-collaborative effort, we managed to collect 84 uLMS samples, representing to the best of our knowledge the largest unbiased genetic study focusing on uLMS.
Material and Methods

Samples, clinical data and availability of sequencing data
In total, 27 fresh-frozen (FF) and 35 formaldehyde-fixed paraffin-embedded (FFPE) tumor samples were collected from 62 chemo-na€ ıve uLMS patients. While 20 FF, 5 FFPE and 4 normal myometrium samples were collected from the University Hospital of Leuven (Belgium), Vall d'Hebron University Hospital Barcelona (Spain) and Turku University Hospital (Finland) contributed 13 and 11 FFPE tumor samples, respectively. Charles University in Prague -1st Faculty of Medicine (Czech Republic) provided 2 FF and 6 FFPE tumor samples and University Hospital Arnau de Vilanova (Lleida, Spain) provided 5 FF samples. Two of these FF samples and their matched blood samples (Leuven) were subjected to whole-genome sequencing (WGS) and analyzed separately. A scheme of all tumor samples and analyses to which they were subjected is displayed in supplementary Figure S1 . Of the 62 collected samples that were evaluated by expert pathologists within each center, 57 samples were What's new? The molecular genetic basis of uterine leiomyosarcoma (uLMS), a rare but extremely lethal cancer type, remains poorly characterized. Through an integrated analysis of genomic and transcriptomic data generated in a large cohort of 84 uLMS patients, here the authors identified several cancer driver genes contributing to uLMS. Most of these genes are known cancer drivers (TP53, RB1, etc.), whereas several others (CCNE1, FGFR, etc.) represent potential therapeutic targets for which drugs are already available or being developed. The data also identified VIPR2, a negative regulator of smooth muscle cell proliferation, as a potential novel tumor suppressor gene in uLMS.
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centrally revised at the University Hospital Leuven by our local expert pathologist Prof. Philippe Moerman. This was done based on haematoxylin-eosin (H&E) slides provided to him. The 5 remaining samples were also revised by Prof. Moerman, but H&E images were digitally provided to him by the respective centers. All revised samples were confirmed to be uLMS. Patients' written informed consent and approval by the Medical Ethical Committee (kU/UZ Leuven) was obtained. Clinical data were collected and staging was performed according to International Federation of Gynecology and Obstetrics (FIGO) 2009. Additional data of 24 uLMS and 122 euLMS were retrieved from The Cancer Genome Atlas (TCGA; http://gdac.broadinstitute.org/). Raw sequencing data have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession numbers E-MTAB-5773, E-MTAB-5764, E-MTAB-5902, E-MTAB-5763 and E-MTAB-5762.
Copy number analysis
DNA of 25 FF tumor samples was processed on Illumina HumanCytoSNP-12 single nucleotide polymorphisms (SNP) arrays. The DNA isolation process is described in supplementary methods. Processing of DNA samples, hybridization, staining, scanning of the BeadChips and primary data extraction were performed according to the Illumina Infinium protocol. Raw copy numbers were corrected for CG-nucleotide using PENNCNV. Results were further processed using Allele-Specific Copy number Analysis of Tumours (ASCAT; v2.1) 13 correcting for stromal infiltration and overall ploidy to infer copy numbers of both alleles. DNA of 35 FFPE tumor samples was subjected to low-pass whole-genome sequencing at an average read depth of 0.0913 (interquartile range: 0.042-0.113) on a HiSeq 2000 using 51 bp single-end reads, as described previously.
14 Reads were mapped to hg19 using Burrows-Wheeler Aligner (v0.7.10) and deduped by Picard (v1.119). Somatic copy number alteration (SCNA) profiles with a 100 Kb bin size were pre-processed using QDNAseq (v1.2.4) and segmented by ASCAT. SCNA profiles were corrected for tumor purity and ploidy was estimated by ABSOLUTE (v1.6). 15 Additional SCNA data were downloaded from TCGA (gdac.broadinstitute.org), from Barretina et al. . [16] [17] [18] Samples were processed by ASCAT when allelic data were available and by ABSOLUTE when only the logR was available. To harmonize SCNA data derived from SNP array profiling and low-pass whole-genome sequencing (Shallow-Seq), we converted data obtained from the latter into a format similar to that obtained from the former. Briefly, we first binned sequencing reads obtained by Shallow-Seq into regions of 100 Kb. We then counted, normalized and analyzed these using QDNAseq and segmented the resulting logR values into "copy numbers" using ASCAT. Next, to harmonize the SCNAs with those obtained by SNP array profiling, we overlapped each 100 Kb bin with the genomic positions covered by the SNP array. Each SNP position was then assigned the copy number value of the segment in which it was located. In case a 100 Kb segment did not contain any position covered by the SNP array, the data were dropped. Vice versa, genomic positions on the SNP array that did not overlap with a segment were also dropped. To prove that one platform is not more sensitive than the other, we calculated the number of breakpoints as a proxy for the number of SCNAs. By means of a t-test we demonstrated that the number of breakpoints did not differ between samples analyzed by SNP array vs. Shallow-Seq (p 5 2.0E-01). Particularly, the number of breakpoints detected by SNP array was 93.4 (range: 32-231) compared to 107.0 by Shallow-Seq (range: 65-216). Genomic Identification of Significant Targets in Cancer (GIS-TIC; v2.0.22) analysis was performed to identify recurrently amplified and deleted regions, using the following settings: a noise threshold of 0.3, a broad length cut-off of 0.5 chromosome arms, a confidence level of 95% and a copy-ratio cap of 1.5. 19 Regions were significantly recurrently affected at the GISTIC cut-off of q < 2.5E-01. The residual q-value was obtained after the removal of overlapping regions that increase the region's significance. The ) and high-level amplifications (CN > 2 1.9 ), based on the categorization by Zack et al. 20 Hierarchical clustering of SCNAs was performed in R, using the presence or absence of focal and broad amplifications and deletions per samples as input matrix. The hierarchical clustering used ward. D as agglomeration method and the Hamann coefficient (R-package ade4 v1.7-4) as distance function, as described by Kandoth et al. 21 Pathway analysis was performed on peaks with 50 genes using the Ingenuity Pathway Analysis (IPA) software.
Survival analysis
All survival analyses were performed by Cox regression using the survival R-package, and corrected for age at diagnosis, tumor size (continuous variables), FIGO stage and the center from which the tumor sample was obtained (categorical variables). Since TCGA did not provide staging information, TCGA samples were excluded from this analysis.
Recurrently affected regions from whole-genome sequencing DNA of 2 uLMS tumor-normal pairs was sent to Complete GenomicsV R for WGS, mapping, variant calling, copy number analysis and structural variation calling (ArrayExpress Accession IDs: E-MTAB-5764 and E-MTAB-5902). The samples were sequenced using DNA Nanoball technology (Complete Genomics) resulting in 195.0-230.9 Gb of mate-pair reads (2 3 35 bp). Mapping against reference genome hg18 resulted in a coverage of 46.83 and 63.83 for both samples. To identify regions that were more often affected by an SCNA than would be expected by random chance, we built a statistical model based on Monte Carlo random sampling. Based on 10,000 simulations, a probability estimation was calculated for each SCNA, while correcting for genomic features such as SCNA replication timing, the fractal structure of the genome and the distance to centromeric and telomeric regions. To estimate the probability, we counted for each base the number of random genomes that sustained the same event at that base. These probabilities were used to calculate the joint probability of observing the established events in both genomes by chance. In particular, while randomly distributing the events over the genome, we took into account that the two boundaries of an event are more likely to be found in regions with the same replication time than in regions with a different replication time. Replication timing data were obtained from Chen et al. 22 Since the breakpoints within 1 Mb from telomeres and centromeres behave differently 23 and uLMS have a noteworthy amount of events close to telomeres and centromeres, these breakpoints were treated differently. Our model ensures that (i) replication timing is considered while randomly distributing events with none of their boundaries close to telomeres or centromeres, (ii) events observed close (<1 Mb) to telomeres and centromeres are randomly distributed, (iii) events such as whole-arm or whole-chromosome loss are modeled as such, thereby losing the original length of the event. Pathway analysis (IPA) was performed and p-values were corrected for multiple testing using the false discovery rate (FDR).
RNA expression and gene fusion analysis
The RNA isolation process is described in supplementary methods. RNA sequencing (RNA-Seq) was performed on 24 tumor samples and 4 normal myometrium samples (RNA Integrity Number >8) using Illumina HiSeq2000. 24 On average, 19.38 million reads were generated per sample (range of 10.16-92.34 million; data are available through ArrayExpress Accession ID: E-MTAB-5762). Briefly, reads were mapped on the Ensembl transcriptome build 37.75 using Tophat2 and Bowtie2. Reads per gene were counted using the HTSeq Python package and transformed into counts per millions. Differential expression was assessed using edgeR, while correcting for GC-content using DESeq. IPA pathway analysis was performed on differentially expressed genes. To assess the relative expression of an individual gene in an individual sample to its distribution in normal tissue, we used the z scores (http://www.cbioportal.org/). Genes with a z scores >2 or <22 were assumed to be respectively up and downregulated. Unsupervised hierarchical clustering of RNA expression data was performed in R, using the normalized counts per million of the top 15% genes with the highest standard deviation as input matrix.
Fusion genes were identified from RNA-Seq data of 8 uLMS samples using deFuse (v0.4.3). 25 Identified fusion genes were verified by designing primer-pairs spanning the breakpoint. After PCR amplification, amplicons were Sangersequenced.
Mutation calling
We called somatic mutations from RNA-Seq data in 24 tumors using the Genome Analysis Toolkit RNA pipeline. 26 Since no matched RNA from healthy tissue was available, mutations were stringently filtered using SNPSift (v4.1 g). Mutations were considered SNPs when they met any of the following criteria: (1) common in dbSNP142; (2) Mutations were further processed using the SNPiR pipeline, 28 a tool specifically designed for mutation calling in RNA. Annotation was performed using ANNOVAR. 29 To detect pathways enriched for mutations, we used Genome MuSiC (v0.4), which takes background mutation rates into account and assigns weights depending on the number of tumors and genes affected in a given pathway.
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Integration of data and pathway analyses
Copy numbers, differential expression, fusion and mutation data were integrated and a combined output was generated using the OncoPrinter tool (http://www.cbioportal.org/oncoprinter.jsp). Furthermore, 4 IPA pathway analyses were integrated and a combined p-values using Fisher's method was generated. Correction for multiple testing was performed using FDR.
Cell proliferation assay
The IncuCyteV R Live Cell Analysis System (Essen BioScience, Pittsfield Charter Township, Michigan) was used for realtime measurement of cell proliferation. SK-UT-1 uLMS cells (from ATCC) were seeded in TPPV R 96-well plates (5000 cells/well) in RPMI1640 medium containing 1% of fetalbovine serum. After 24 hr, cells were treated with vasoactive intestinal peptide (VIP; 1 mM, 10 mM or 15 mM, Tocris, Abingdon, UK) or vehicle and cell proliferation was monitored for 210 hr. To compare the growth of treated cells with untreated cells over time, two-way repeated measures ANOVA was carried out with Bonferroni post-tests.
Results
Patient characteristics
The 84 uLMS patients included in the study had a median age of 57 years (range: 27-82). All tumors were high-grade and 90% of them were collected during primary resection. While 53% of patients had stage I disease, up to 25% had stage IV disease. Tumor size varied from 2.5 to 35 cm with a median of 9.7 cm. None of the patients were treated prior to sampling and half of the patients received adjuvant treatment. PFS and OS data were available for 59 (70%) patients and for 83 (99%) patients, respectively. The estimated median PFS and OS were 20 6 3 and 316 8 months, respectively. All clinical characteristics are summarized in Table 1 , and a scheme displaying each uLMS sample, its origin and the genetic analysis it was subjected to is shown in supplementary Figure S1 .
Uterine leiomyosarcomas are chromosomally unstable
By determining SCNAs in 84 uLMS, we found that on average 34 6 19% of the uLMS genome was deleted and 9 6 9% affected by amplifications, and that there were 110 6 78 somatic chromosomal breakpoints per tumor. When using GISTIC to identify SCNAs that were significantly enriched in uLMS, 19 we frequently observed whole-arm deletions (q < 2.5E-01 for 29 chromosomal arms), affecting chromosome 10q (including PTEN), 16q, 19q, 22q and Xq (supplementary Table S1 ). We also detected focal SCNAs: 31 regions were deleted and 10 regions were amplified at q < 2.5E-01 (Table 2 and supplementary Table S2 ). As expected, there was a correlation between the SCNA profile of uLMS and euLMS samples (r 2 5 0.82 and 0.34 for deletions and amplifications, respectively). Therefore, we pooled 84 uLMS and 122 euLMS samples from different public resources (see Methods) and focused on refining chromosomal regions identified in uLMS alone using this much larger sample set (n 5 206). Particularly, by performing a second GISTIC analysis we were able to narrow down the 41 uLMS regions and refine the number of genes located in them (Table 2) .
Next, to identify novel cancer genes underlying uLMS, we selected 238 genes located in focal SCNA regions and included in one of following cancer databases: the Catalogue of Somatic Mutations in Cancer (COSMIC; http://cancer. sanger.ac.uk/cosmic), oncogenes and tumor suppressor genes (TSG) listed by UNIPROT (http://www.uniprot.org/) and the TSG database (TSGene; http://bioinfo.mc.vanderbilt.edu/ TSGene/). All selected genes were then evaluated for their established role as a TSG or oncogene in the PubMed literature. This allowed us to select several oncogenes as driver genes in minimally amplified regions (Table 2) , including 8q24.21 (MYC), 1q21.1 (BCL9), 19q12 (CCNE1) and 12q15 (MDM2). The following minimally deleted regions and potential TSGs were identified: 13q14.2 (RB1), 2q37.3 (ING5), 1p36.32 (TP73, PRDM16), 4q35.2 (ING2), 2p25.3 (RHOB), 11q24.3 (OPCML) and 17p13.1 (TP53). Since cancer consensus genes are more easily identified in narrow regions containing a limited number of genes, we performed an IPA pathway analysis on focal peaks containing 50 genes. This revealed that pathways involved in D-glucuronate degradation I, estrogen-mediated S-phase entry, bladder cancer signaling and various other cancer signaling pathways were enriched (p < 5.0E-02; supplementary Table S3) .
We then explored the prognostic value of each SCNA region using a Cox regression survival analysis, while Table S4 ). In addition, the copy number status of each driver gene of interest in these regions ( OCLN encodes a tight-junction protein, whereas VIPR2 is a negative regulator of smooth muscle cell proliferation. 31 No amplified regions correlated with survival. In addition, we compared outcomes of patients with diploid vs. tetraploid tumors, showing that tetraploid uLMS had unfavorable outcome compared to diploid uLMS (median OS 5 19.0 vs. 48.0 months; p 5 3.2E-03; Fig. 1c) .
Unsupervised hierarchical clustering of SCNA data revealed three distinct SCNA clusters, of which cluster 2 had a significantly shorter OS than the other clusters by multivariate analysis (HR 5 5.4, CI 5 1.2-24.6, p 5 2.9E-02; Figs. 1a and 1b). Table 1 shows the clinical characteristics associated with each cluster. Interestingly, cluster 2 was characterized by 17q11.2 and 2q14.1 deletions, which often co-occurred (v 2 p 5 3.5E-07). Chromosomal region 17q11.2 contains NF1, which is an established TSG, whereas 2q14.1 contains multiple candidate TSGs, including BIN1, RND3, LRP1B and C2orf40.
Whole-genome sequencing for in-depth characterization of SCNAs
To better characterize SCNAs, we performed WGS on 2 uLMS and matched germ-line DNA samples at high depth (>603). Both were selected to be tetraploid, as confirmed by flow cytometry. Each sample was characterized by numerous deletions (39.6% and 22.3% of the genome) and amplifications (6.6% and 3.3%), and showed evidence of chromothripsis (supplementary Fig. S2 ). When distinguishing between SCNAs occurring before and after the tetraploidy event (based on observed allelic frequencies; see Methods), we found that 74% and 61% of the deletions and amplifications occurred before tetraploidization, respectively. Interestingly, some genomic regions were affected by an SCNA twice, i.e., before and after tetraploidization. Using a statistical model based on Monte Carlo random sampling to identify regions that were more often affected than expected by random chance, a probability estimation was calculated for each SCNA. Overall, this simulation identified 29 genomic regions (10 amplifications and 19 deletions) for which the random chance of being affected by an SCNA twice was very low (p < 5.0E-03; supplementary Table S5 ). Interestingly, pathway analysis of genes located in these 29 regions revealed that the PTEN pathway (FDR 5 2.4E-02), the glioblastoma multiforme signaling pathway (FDR 5 3.6E-02) and the PI3K/AKT pathway (FDR 5 6.3E-02) were enriched (supplementary Table S6 ). Of these 29 regions, 15 were also identified by GISTIC in the 84 uLMS samples (supplementary Table S5 ).
Integrated gene expression and SCNA analysis
Next, we subjected 24 uLMS samples (supplementary Fig. S1 ) to transcriptome sequencing to identify differentially expressed genes in uLMS. Overall, 1,487 and 669 genes were significantly up or downregulated compared to normal myometrium (FDR < 5.0E-02; supplementary Table S7 ). Pathway analysis of these 2,156 differentially expressed genes revealed overrepresentation of pathways including: cAMP-mediated signaling (ENPP6, GRM2, PTGER3, VIPR2), cell cycle control of chromosomal replication (CDC45, RPA3, CDC6), mitotic roles of polo-like kinase (KIF23, CDC25C, CDC20) and Columns from left to right: center of origin from which the sample was obtained (Barcelona, green; Leuven, orange; Prague, purple; Lleida, pink; Turku, yellow; TCGA, light green), cluster membership when clustering all 84 uLMS samples (cluster 1, green; cluster 2, orange; cluster 3, blue), sample ploidy (diploid, orange; triploid, blue; tetraploid, pink) and sample purity (0%, white; 100%, dark red). (b and c) Kaplan-Meier OS plots in months for cluster membership and ploidy, with the median survival in months between brackets. [Color figure can be viewed at wileyonlinelibrary.com]
estrogen-mediated S-phase entry (CCNA2, CCNE2, CCNE1, ESR1; supplementary Table S8 ). Among the 5,651 genes located in the 31 deleted regions identified by GISTIC, 151 genes were significantly downregulated (Table 2) , including PRDM16 (FDR 5 4.4E-02) and VIPR2 (FDR 5 2.2E-03). Also expression of PTEN was significantly decreased (FDR 5 2.5E-02). Interestingly, VIP (FDR 5 2.3E-06) and PACAP (FDR 5 5.4E-02), the two VIPR2 ligands, were also downregulated in uLMS. Among the 566 genes located in the 10 amplified regions, 37 genes were significantly overexpressed ( Table 2) . Notably, expression of TDO2, a gene previously reported to be overexpressed in metastatic uLMS, was 99-fold increased compared to normal myometrium (FDR 5 1.2E-09). 32 Likewise, CCNE1 was amplified and its expression 16-fold increased (FDR 5 1.9E-05).
Unsupervised hierarchical clustering of these transcriptome data identified 2 expression clusters, one cluster consisting of 11 samples and another consisting of 13 samples (supplementary Fig. S3 ). Both expression clusters overlapped substantially with the SCNA clusters described above. Particularly, 10 out of 11 samples from expression cluster 1 belonged to SCNA cluster 1, while 10 out of 13 samples from the second expression cluster were classified in SCNA cluster 2 or 3 (v 2 p 5 3.7E-03). Interestingly, VIPR2 expression was significantly lower in expression cluster 2 vs. cluster 1 (FDR 5 1.2E-09). Patients in expression cluster 2 were also characterized by a shorter median overall survival (21 months) than patients in cluster 1 (43 months), but in contrast to the SCNA cluster analysis, this difference was not significant (p 5 2.1E-01).
The mutation landscape of uLMS
We then screened for somatic mutations in the 24 tumor samples subjected to RNA-Seq. Overall, we retrieved 2,258 mutations, of which 1,486 were exonic non-synonymous mutations and 45 represented indel mutations. In total, 40 genes were mutated in 3 samples (supplementary Table  S9 ). The most frequently affected gene was TP53, which was mutated in 10 patients (41.7%; supplementary Fig. S4) . Furthermore, we observed that MED12 (mediator complex subunit 12), which plays a role in transcription initiation, was mutated in 3 samples (12.5%; supplementary Fig. S4 ). Other mutated genes included the translation initiation factor EIF3A (16.7%), proto-oncogenes ABL1 and IGF2R (both 12.5%), NFkB, checkpoint kinase ATR and DNA repair proteins RAD50 and BRCA1 (all 8.3%). Also, three members of the laminin family (LAMA2, LAMA4 and LAMC1) were mutated in 6 different samples. LAMC1, a laminin that plays a role in migration, was recently shown to be involved in uterine carcinoma progression. 33 In addition, Genome MuSiC applied on all exonic nonsynonymous mutations and indels identified 46 pathways as significantly mutated (FDR < 5.0E-02; supplementary Table  S10 ). Most significantly mutated pathways were related to ATM-, ATR-or BRCA-mediated DNA damage responses, transcription and cancer. We considered genes involved in pathways with an FDR < 1.0E-03 as genes of interest (supplementary Table S9 ). Interestingly, one sample was characterized by a 10-fold increase in mutation load compared to the other uLMS samples (656 vs. 70; p 5 2.4E-64). This tumor was also highly chromosomally unstable, as we detected 134 breakpoints and 46% of the genome was affected by deletions. Furthermore, its mutation signature revealed that 57% of mutations were characteristic of a deficient mismatch repair (supplementary Fig. S5, supplementary methods) . Indeed, the mutation signature underlying this tumor was clearly different from other uLMS samples, for which the age-related mutation signature was the main contributor. This sample harbored an MSH2 (mutS homolog 2; p.D514N) mutation, which could point to microsatellite instability.
uLMS is characterized by various gene fusion events
Furthermore, since RNA-Seq was performed using pairedend sequencing on 8 (out of 24) random uLMS samples (supplementary Fig. S1 ), we could also detect fusion transcripts in these samples. Overall, we identified six fusions, none of which have previously been reported for uLMS. Intriguingly, one sample showed a YWHAE-TWSG1 fusion. YWHAE is frequently found in fusions with NUTM2A/B in high-grade endometrial stromal sarcomas (HGESS), highgrade uterine sarcomas that arise from the endometrium instead of the myometrium. 34 Another uLMS sample was characterized by a RB1-MTMR3 fusion. Interestingly, RB1 was also frequently affected by chromosomal deletions (Table  2) . A FNDC3A-DIAPH3 fusion was detected in another uLMS. While FNDC3A does not have a clear function in cancer, low DIAPH3 levels have been linked to metastasis. 35 One uLMS harbored three fusion genes: TNS1-RET, POLR1A-LDB3 and WAPL-AC016910.1. TNS1 encodes tensin 1, which crosslinks actin filaments and acts as an oncogenic driver in chromosomally unstable colorectal cancer. 36 RET encodes a proto-oncoprotein involved in cell proliferation, migration and differentiation and has been involved in gene fusion events, e.g. in thyroid carcinoma. 37 WAPL ensures correct chromatid cohesion and division during mitosis. WAPL overexpression causes tumor progression, while its repression induces cell death in cervical cancer cells. 38 Integrative profiling to reveal cancer driver genes and pathways in uLMS Next, we integrated pathways identified on the separate SCNA, mutation and gene expression data. Overall, we identified 12 pathways that were significantly altered after correction for multiple testing, all of which were cancer-and cell cycle-related (Table 3 ). In addition to PTEN signaling (IGF1R, IGF2R, PIK3R1, PTEN, etc.), affected pathways included G1/S checkpoint regulation (ABL1, CCNE1, TP53, MDM2, MYC, etc.) and molecular mechanisms of cancer (ABL1, FRS2, MDM2, MYC, etc.). Interestingly, these pathways contain multiple genes for which targeted drugs are available, either approved or still in clinical trial testing for other cancer types.
Finally, to assess which genes were most frequently affected in uLMS, we also integrated SCNA, mutation and gene expression data for the 24 uLMS samples, of which gene fusion data were available in 8 samples (supplementary Fig. S1 ). To evaluate expression deviations in each individual sample, we assigned for each gene the z scores, a measure reflecting the difference in expression between tumor and normal myometrium (see Methods). We considered genes with a z scores >2 or <22 as affected at the gene expression level. 39 Overall, we identified six genes that were affected by various genetic aberrations in almost all uLMS. First, we found that aberrations in TP53, RB1 and PTEN occurred in respectively 92%, 88% and 75% of uLMS (Fig. 2) . RB1 and PTEN were mainly affected by deletions (88% and 71%), while PTEN was also downregulated (58%). TP53 was mutated in 42% and deleted in 33% of uLMS, whereas its expression was significantly reduced in 33% of samples. YWHAE, which is a known fusion partner in HGESS, was detected as a fusion partner in one uLMS, while in up to 14 samples (58%) its expression was significantly increased. While MED12 was mutated in 12.5% of uLMS, we additionally observed that MED12 was affected by SCNAs and expression changes in 46% and 25% of cases, respectively. Finally, VIPR2 was affected in 96% of uLMS. Particularly, its expression was downregulated in 75% of samples whereas in 37.5% of tumors it was affected by a deletion. Together with our observation that patients with VIPR2 deletion have shorter OS, these findings suggest VIPR2 as a novel TSG in uLMS.
To further characterize the role of VIPR2 in uLMS, we assessed VIPR2 protein expression by immunohistochemistry in 17 uLMS FFPE samples and 5 healthy myometrium samples (see supplementary methods). Using a semi-quantitative scoring system, 40 we found that 4/5 myometrium samples and 10/17 uLMS samples could be categorized as "positive." The mean scores were 5.18/8 for uLMS samples and 6.00/ 8 for myometrium samples. Although we noted slightly more staining in normal myometrium, this difference was not significant (representative images shown in Fig. 3a) . For a more quantitative analysis, we then determined by western blot VIPR2 protein expression in 4 uLMS and 3 myometrium samples for which sufficient FF tissue was available (see supplementary methods). Ratios of VIPR2/b-actin signal were significantly lower in uLMS samples than in myometrium -03  ABL1, CAMK2B, CDKN2A, CDKN2C, CDKN2D, E2F1, E2F2, EGF,  FGFR4, FRS2, IGF1, IGF1R, IGF2R, MDM2, PDGFC, PDGFD,  PIK3R1, PLCG2, PTEN, RB1, TFDP1, samples (t-test p 5 5.8E-0.3; Fig. 3b ). Overall, these findings suggest decreased VIPR2 expression in uLMS. Interestingly, VIPR2 is a negative regulator of smooth muscle cell proliferation. 31 Hence, we hypothesized that stimulation of the VIPR2 receptor would reduce proliferation of uLMS cells. Since VIPR2 is expressed in the SK-UT-1 uLMS cell line based on western blot analysis (Fig. 3b) , we stimulated VIPR2 in SK-UT-1 cells with different concentrations (1 mM, 10 mM and 15 mM) of VIP, a natural agonist of VIPR2. As expected, VIP decreased cell proliferation in a dose-dependent manner, with 10 mM VIP (p < 1.0E-02) and 15 mM VIP (p < 1.0E-03) leading to a significant difference in cell proliferation when compared to untreated cells (Fig.  3c) . These functional data support our hypothesis that VIPR2 may function as a TSG in uLMS.
Discussion
Here, we integrated genomic and transcriptomic data to provide novel insights into the molecular genetic determinants underlying uLMS. For each type of genetic abnormality, we identified numerous potential cancer genes or pathways, several of which were interesting because they represent established cancer drivers for which sometimes targeted drugs are already available. Furthermore, an integrative analysis of each of these abnormalities identified TP53, RB1, PTEN, YWHAE, MED12 and VIPR2 to be affected in the majority of uLMS.
First, we identified three well-established tumor suppressor genes, i.e., TP53, RB1 and PTEN, which were altered in 92%, 88% and 75% of uLMS, respectively. TP53 was the most frequently mutated gene (42%), which is in accordance with previous reports, 12 but was also recurrently deleted and downregulated in 33% of uLMS. RB1 was deleted in 88% of tumors, and interestingly, it was also involved in a gene fusion event. RB1 inhibits cell cycle progression and loss of RB1 function is often associated with chromosomal instability, a characteristic of uLMS. 41 PTEN negatively regulates PI3K/ AKT/mTOR signaling and was mainly affected by deletions (71%) resulting in significantly reduced expression in 58% of uLMS patients. The PI3K/AKT/mTOR pathway plays an important role in cancer-related processes such as cell growth, survival and apoptosis 42 and was also identified as one of the key pathways affected by SCNAs. These findings are in line with our previous results, where we identified dual PI3K/ mTOR inhibition as an effective therapeutic strategy in uLMS patient-derived xenografts. 40 Furthermore, several PI3K/mTOR inhibitors are currently tested in clinical trials for sarcomas or other cancers, including the mTOR inhibitor sapanisertib and the PI3Ka inhibitor serabelisib. Another frequently affected gene that showed aberrations in 83% of uLMS and overexpression in 58% of tumors was YWHAE. This gene belongs to the 14-3-3 family of regulatory proteins that mediate signal transduction through protein-protein interactions and are involved in apoptosis and cell cycle regulation. 43 Although gene fusions involving YWHAE are common in HGESS, which represent a different subtype of uterine sarcomas, we here report for the first time a YWHAE-fusion in uLMS. Preclinical data, including YWHAE-NUTM2A/B knockdown studies, suggest 14-3-3 proteins as therapeutic targets, with 14-3-3 protein-protein interaction inhibitors currently being developed. 34, 43 We also identified MED12, which was affected in 63% of uLMS, with mutations being present in 12.5% of cases. MED12 encodes a subunit of the Mediator complex, which can both repress and activate gene transcription. 44 Surprisingly, we not only observed amplifications or overexpression of MED12 (12.5% and 17%), but also deletions and downregulation (33% and 8%). Indeed, at present, the role of MED12 in uLMS remains unclear and functional studies are needed. 44 Finally, our integrated analysis also revealed that VIPR2, a gene not yet implicated in any type of cancer, was frequently affected in uLMS. Particularly, VIPR2 was downregulated or deleted in respectively 75% and 37.5% of uLMS. Patients with a VIPR2 deletion were also characterized by shorter survival, suggesting that absence of VIPR2 triggers a more aggressive uLMS. Since VIPR2 plays a role in smooth muscle cell proliferation, 31 the cell type that is affected in uLMS, we hypothesized that VIPR2 could be a novel TSG underlying uLMS. To functionally test this hypothesis, we stimulated VIPR2 in uLMS SK-UT-1 cells using its natural agonist VIP. We observed that exposure to VIP decreased cell proliferation in a dose-dependent manner, confirming a potential tumor suppressor function for VIPR2 in uLMS. Interestingly, since the anti-depressant drug imipramine has been shown to upregulate VIPR2 expression, its repurposing could represent a potential therapeutic strategy for uLMS. 45 Besides these six genes that were affected in the majority of uLMS, we identified several other cancer driver genes that possibly contribute to uLMS. Particularly, we integrated 
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SCNA with gene expression data and identified several established oncogenes that were both amplified and overexpressed in uLMS. Of these, cyclin E1 (CCNE1) and tryptophan 2,3-dioxygenase (TDO2) were the most relevant and promising. Expression of CCNE1 was up to 16-fold increased in uLMS and is known to induce chromosome instability in various cancer types including serous ovarian carcinoma. 46 As such, CCNE1 overexpression may partly explain the high degree of chromosomal instability observed in uLMS. While no cyclin inhibitors are available, cyclin function can be blocked by cyclin-dependent kinase (CDK) inhibitors such as palbociclib, which is in phase III trials for breast cancer, and ribociclib, which is in early-phase clinical trials for sarcomas. Expression of TDO2 was 99-fold increased in our sample set, suggesting it might be a target in uLMS. By degrading tryptophan, TDO2 generates kynurenine, a metabolite that suppresses the antitumor immune response. 47 Promising results have been achieved when inhibiting TDO2 in mastocytoma-bearing mice, but preclinical studies in sarcomas have yet to be performed. 47 Other oncogenes frequently affected by amplifications included MYC and MDM2. We also identified several genes that were frequently deleted and downregulated and that are known to act as TSGs. For instance, PR/SET domain 16 (PRDM16) was frequently affected by deletions and recently has been shown to be a TSG contributing to leukemia. 48 Interestingly, PRDM16 knockdown in brown fat precursors triggers muscle differentiation and its loss has previously been reported in 8 of 20 (mainly extrauterine) LMS. 9 Another interesting gene previously reported to be mutated in uLMS is ATRX, which encodes a chromatin remodeler. 12 In our set of 24 samples that were screened for mutations we detected 2 mutations. In addition, the 2 samples that were analyzed by WGS were also mutated. Overall, 4 samples (15.4%) were thus affected by ATRX mutations, which is a frequency similar to that observed in previous studies. 12, 49 Finally, we performed an integrated pathway analysis to identify cancer-related pathways overrepresented in uLMS. Interestingly, some of these pathways contained genes for which targeted treatment options are available or being developed. Particularly, the G1/S checkpoint regulation, molecular mechanisms of cancer, PTEN signaling and estrogenmediated S-phase entry pathways were overrepresented in uLMS. Of the latter pathway, several of the cyclins (CCNE1 and CCNE2) in addition to E2F transcription factors (E2F1/ 2), which all play a role in cell cycle progression, were overexpressed. Another gene of interest in some of these pathways was fibroblast growth factor receptor FGFR4. FGFRs can be blocked not only by multi-targeted compounds such as pazopanib, which is already approved for uLMS, but also by FGFR-specific inhibitors including BGJ398 and AZD4547.
Since uLMS are rare tumors, it is challenging to assemble large sample collections. Most publications that characterize uLMS typically include <50 samples. Also in our study, the most important limitation was the limited availability of LMS samples (n 5 84). To narrow down recurrently affected SCNA regions, we therefore relied on euLMS samples. To ensure that we only identified uLMS-specific SCNAs, these euLMS samples were only used to refine regions already identified in uLMS. Another limitation involves the limited availability of FF samples included in the study. Indeed, for most patients only FFPE material was available. Since RNA sequencing demands FF material, this could only be performed for the 24 FF samples and as a result data integration with gene expression data was restricted to this more limited set of samples.
Overall, based on the integration of genomic and transcriptomic data generated in a large cohort of 84 uLMS patients, we were able to identify several cancer driver genes contributing to uLMS. Most of these were genes previously established as cancer drivers (TP53, RB1, etc.), whereas several other genes (CCNE1, FGFR, etc.) represent potential therapeutic targets, for which drugs are already available or being developed. Finally, we also identified a potential novel TSG VIPR2, deletion of which was associated with a more aggressive form of uLMS.
